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The present study is performed to investigate the inhibitory eﬀects of Radix Adenophorae extract (RAE) on ovalbumin-induced
asthma murine model. To study the anti-inﬂammatory and antiasthmatic eﬀects of RAE, we examined the development of pul-
monary eosinophilic inﬂammation and inhibitory eﬀects of T cells in murine by RAE and cyclosporine A (CsA). We examined
determination of airway hyperresponsiveness, ﬂow cytometric analysis (FACS), enzyme-linked immunosorbent assay (ELISA),
quantitative real time (PCR), hematoxylin-eosin staining, and Masson trichrome staining in lung tissue, lung weight, total cells,
and eosinophil numbers in lung tissue. We demonstrated how RAE suppressed development on inﬂammation and decreased air-
way damage.
Copyright © 2008 Seong-Soo Roh et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
RadixAdenophoraeisadryrootofUmbelliferaeadenophora
triphilla var. japonica Hara. Radix Adenophorae has the ac-
tions of reinforcing phagocytosis of giant cell, rising leuko-
cyte, regulating humoral and cellular immunity, antimuta-
tion, restraining adenocarcinoma cell, strengthening cardiac
function, allaying a fever, and easing pain and cough [1].
It has researched that Radix Adenophorae has the chem-
i c a l ss u c ha sc y c l o a r t e n y la c e t a t e ,l u p e n o n e ,β-sitosterol,
taraxerone, octacosanoic acid, and praeruptorin A [2]. These
chemicals are known to possess anti-inﬂammatory and im-
munomodulatory activity [3–7].
In modern clinical medicine, it can cure atrophic gas-
tritis, pneumonia, thrush, lung cancer, pharyngolaryngi-
tis, infective inﬂammation of trachea and lungs kinds of
eosinophilic inﬂammation, and bronchial hyperresponsive-
ness [8]. And asthma is a chronic inﬂammatory disease of
the mucosa and is associated with excess production of Th2
cytokines(IL-4,lL-5,IL-13),eosinophilicinﬁltrationinlung.
Th2 cells play a critical role in the pathogenesis of al-
lergy and asthma [9] and eosinophils have a crucial role
in the pathogenesis of allergic diseases and produce factors
such as CCR3, CCR5, EOTAXIN 2, TGF-β1, and TARC.
The inﬂammatory aspects of the disease are complex with
mast cells, dendritic cells, and T and B lymphocytes, and
eosinophils playing important roles. Increased eosinophils
and T lymphocytes in the bronchial mucosa and bron-
choalveolar lavage ﬂuid (BALF) are distinctive features of the
inﬂammatory response in patients with asthma and appear
to correlate with the severity of the disease [10–12].
Clinically Radix Adenophorae has been used for treat-
ment of asthma in Korea. But a research for this has not
been accomplished yet. So to clarify the anti-inﬂammatory
and antiasthmatic eﬀects of Radix Adenophorae (RAE) and
cyclosporine A(CsA), we examined the inﬂuence of RAE and2 Mediators of Inﬂammation
CsA on the development of pulmonary eosinophilic inﬂam-
mation in murine model of asthma.
Therefore, we decided to investigate the eﬀects of Radix
Adenophoraeontotalpulmonaryairﬂowinmice,eosinophil
inﬂux, total leukocytes number, cell surface markers by
FACS, and cytokines production in BALF by ELISA were de-
termined.
2. MATERIALS AND METHODS
Plant material and Radix Adenophorae of extracts. The sam-
ple of the Radix Adenophorae was purchased from Oriental
Medical Hospital (Daejeon, South Korea) in 2007. The plant
was identiﬁed by Professor Young-Bae Seo and avoucher
specimens (Adenophorae) are deposited in our laboratory.
Plantmaterial(200g)wasextractedthreetimeswithdistilled
H2O (or distilled water). Then, the extract was ﬁltered and
evaporated on a rotary evaporator (BUCHI, Switzerland),
dried by a freeze drier (EYELA FDU-540, Tokyo, Japan) to
yield the extract of Adenophorae Radix (20g). The yield
(w/w) of the extract was about 10%.
Animals
Seven-eight-week-old female C57bl/6 mice were obtained at
DaehanBiolinkCo.Ltd.(Eumsung,SouthKorea).Allanimal
procedureswereconductedinaccordancewiththeguidelines
of the Institutional Animal Care and Use Committee, Ko-
reaResearchInstituteofBioscienceandBiotechnology(Dae-
jeon, South Korea). We were divided into ﬁve groups and
each group had six mice.
IsolationCD4+ Tcells
Splenocytes were isolated from naive C57bl/6 mice. Cells
were enriched for CD4+ cell populations by ﬁrst staining the
cells with anti-CD4 (BD PharMingen, Calif, USA). CD25-
cells were isolated from this population by ﬁrst staining
with ﬂuorescein isothiocyanate (FITC)—conjugated anti-
CD25 mAb (BD PharMingen) followed by incubation with
magnetic-activated cell sorting anti-FITC beads (Miltenyi
Biotec, Auburn, Calif, USA). CD4+ T cells were selected
on a (CS) column, and the ﬂow-through was collected as
CD4+ T cells. Isolated cells were activated by overnight in-
cubation on 24-well plates coated with 1μg/mL anti-CD3
(datasheet: MCA500GA; description: Rat antimouse CD3;
speciﬁcity: CD3; format: puriﬁed; product type: monoclonal
a n t i b o d y ;c l o n e :K T 3 ;i s o t y p e :I g G 2 a ;q u a n t i t y :0 . 2 5 m g ,
AbD Serotec.), 1μg/mL anti-CD28 (datasheet: MCA1363;
description: Hamster antimouse CD28; speciﬁcity: CD28;
format: puriﬁed; product type: monoclonal antibody; clone:
37.51.1; isotype: IgG; quantity: 0.2mg) and with RAE
(100, 50, 10μg/mL) added to RPMI medium supplemented
with 1 unit/mL penicillin, 1μg/mL streptomycin, 20mM
L-glutamine, 50mM-mercaptoethanol, and 5% FBS for 48
hours after stimulation.
Cytokinemeasurements
After 48-hours cultures, samples were centrifuged at 2000
rpm for 10 minutes, and the supernatants were stored at
−80◦C. Mouse IL-4, IL-5, IL-13, and IFN-γ were quantiﬁed
using ELISA kits (BioSource International, Camarillo, Calif,
USA) according to the manufacturer’s protocols.
Digestionofpulmonarytissueandcellspreparations
Single-cell suspensions from lung tissues and BALF were
isolated by mechanical disruption in RPMI 1640 medium
supplemented with 2mM L-glutamine, 100U/mL penicillin,
100mL streptomycin, 50mM 2-mercaptoethanol, 20mM
HEPES, and 2% heat-inactivated fetal bovine serum (FBS,
GIBCO, Grand Island, NY, USA). Brieﬂy, lungs were sub-
sequently removed from thoracic cavity. After mincing us-
ing sterile scalpels, tissue was incubated in PBS containing
1μg/mL collagenase IV and 2μg/mL dispase II for 40 min-
utes at 37◦C in a sterile polypropylene tube. After incuba-
tion, lung tissue was vigorously pipetted up and down to fur-
ther dissolve remaining tissue clumps and then ﬁltered us-
ing 70μm cellstrainer (Falcon, Le Pont de Claix, France). To-
tal cells were counted manually in a hemocytometer cham-
ber (Fisher). A number of 2 − 4 × 103 cells were spun onto
glass slides (Cytospin centrifuge, Cellspin, Hanil, South Ko-
rea) (400xg for 4 minutes). Diﬀerential count was made ac-
cording to standard morphologic criteria.
OVAsensitizationandinhalation
By modiﬁed protocol as previously described [13, 14], OVA
(500μg/mL) in PBS was mixed with equal volumes of 10%
(w/v) aluminum potassium sulfate (alum; Sigma-Aldrich) in
distilled water. Then incubated for 60 minutes at RT after
adjustment to pH 6.5 using 10 N NaOH, and centrifuged
at 750Xg for 5 minutes. OVA/alum pellet was resuspened
to the original volume in distilled water. The experimen-
tal animals were sensitized by intraperitoneal (i.p) injection
of OVA/alum {500μg/ml, 0.2μg alum-precipitated Ag con-
taining 100μg of OVA (Sigma-Aldrich, Seoul, South Korea)
bound to 4mg of aluminum hydroxide (Sigma-Aldrich) in
PBS} with the amount of 200μg on day 0, and 100mL on
days 7 and 14. And the mice were challenged with an intra-
tracheal (i.t) injection of 100mL OVA/alum (500μg/mL) on
day 21, and underwent an aerosol challenge with OVA/alum
for 30 min/day on 5 days/week for 8 weeks (at a ﬂow rate of
250L/min,2.5%ovalbumininnormalsaline).Sevendaysaf-
terthesecondsensitization,micewereexposedtoaerosolized
ovalbumin for 30 min/day on 5 days/week for 8 weeks (at a
ﬂow rate of 250L/min, 2.5% ovalbumin in normal saline).
The RAE (450, 45mg/kg) in solution form were orally ad-
ministered ﬁve times a week and CsA (10mg/kg) injection
three times a week for the last 8 weeks once 0.1mL. One day
afterthelastoftheOVAexposures,samples(BALF,lungcells,
and blood) were collected.Seong-Soo Roh et al. 3
BALF
To evaluate airway inﬂammation, we experimented the ac-
cumulation of eosinophils in BALF. Mice were sacriﬁced
with an intraperitoneal injection of sodium pentoparbitone
(100mg/kg).Thetracheawascannulatedandtheleftbronchi
were tied for histological experiment.
Immediately after sacriﬁce, cells in the lungs were re-
covered by ﬂushing 1mL of BALF (1mM EDTA, 10% FBS,
PBS) into the lungs via the trachea. Total cell counts were
determined and 100mL of ﬂuid were cytospin onto glass
slides using a cytospin centrifuge (Cellspin, Hanil, South Ko-
rea) (400×gf o r4m i n u t e s ) .D i ﬀerential cell counts were
performed after staining with Diﬀ-Quik Stain Set (Baxter
Healthcare Corporation, Miami, Fla, USA). The supernatant
of BALF was stored at –25◦C for determination of cytokines.
Determinationofairwayhyperresponsiveness
Total pulmonary airﬂow in mice was estimated in a modiﬁ-
cation of the method [15, 16]. Buxco system (Biosystem XA;
Buxco Electronics Inc., Troy, Conn, USA) was used to eval-
uate the extent of airway constriction in diﬀerent groups of
mice following the protocol described previously.
Penh is equal to Pause x PIF/PEF, where Pause = (Te −
Tr)/Tr (PIF: peak inspiratory ﬂow; PEF: peak expiratory
ﬂow; Te: expiratory time; Tr: relaxation time). In this exper-
iment, the mice were aerosolized ovalbumin for 30min/day
on 3 days/week for 12 weeks. Twenty four hours after ﬁnal
inhalation, the mice were given aerosolized normal saline,
50μg/mL methacholine (Sigma-Aldrich). And then airway
reactivitywasmonitoredfor1,3,10,and30minutes,serially.
Diﬀerences of Penh value between groups were evaluated by
means of student’s t-test.
Antibodiesandﬂowcytometricanalysis
All antibodies (CD3, CD4, CD8, CD69, CCR3, CD11b, Gr-1,
IgE, and B220) for ﬂow cytometric analysis were purchased
from Becton Dickinson (BD) PharMingen (San Diego, Calif,
USA).CellsfromlungtissuesandBALFwerestainedwiththe
indicated antibodies in staining buﬀer (PBS containing 1%
FBS and 0.01% NaN3)f o r1 0m i n u t e so ni c e ,a n da n a l y z e d
by two-color ﬂow cytometry on a FACScan using CellQuest
software (BD Biosciences, Mountain View, Calif, USA).
Enzyme-linkedimmimosorbentassay
Interleukin (IL-4, IL-5, IL-13, IL-I0), IgE production from
BALF and histamine release in serum of the indicated mice
(n = 6) was measured by ELISA according to the manufac-
turer’s instruction on a monoclonal antibody-based mouse
ELISAkit.Alldatarepresentthestandarddeviationofatleast
three diﬀerent determinants and were compared using Stu-
dent’s t-test.
Quantitativereal-timePCR
To study antiasthmatic eﬀects of Radix Adenophorae ex-
tract on cytokine gene expression from lung cells, quantita-
tive real-time PCR was performed after quantitative normal-
ization for each gene by a densitometry using β-actin gene
expression. Brieﬂy, total cellular RNA was extracted from
the lung by the phenol-chloroform-based method (RNA-
solB: Tel-Test Co. Inc., Friendswood, Tex, USA) according to
the manufacturer’s instructions. cDNA synthesis from 3μg
of total RNA was carried out using a ReverTraAce-a-cDNA
Synthesis kit (Toyobo Co., Ltd., Osaka, Japan) according to
the manufacturer’s instructions. Real-time quantitative PCR
was performed using the Applied Biosystems 7500 Fast Real-
Time PCR system (Applied Biosystems, Foster City, Calif,
USA) with the following primers.
The primer sequences are as follows: mouse eotaxin
2, 5 -CCTGGACCAAAAACTCCAAA-3  and 5 -GCGACT-
GGTGCTGATATTC-3  CCR3, 5 -CCCGAACTGTGACIT-
TTGCT-3  and 5 -CCTCTGTATAGCGAGGACTG-3  IL-
13, 5 -ATGCCCAACAAAGCAGAGAC-3  and 5 -TGA-
GAGAACCAGGGAGCTGT-3  TNF-α,5  -TGGGAGGAA-
GGGGTCTAAG-3  and 5 -ACCTACGACGTGGGCTAC-
AG-3  IL-10, 5 -AAGCAGCCTTGCAGAAAAGA-3  and
5 -TGGGAAGTGGGTGCAGTTAT-3  TGF-β1, 5 -TGG-
AGCAACATGTGGAACTC-3  and 5 -CTGCCGTACAAC-
TCCAGTGA-3  TARC, 5 -CAGGGATGCCATCGTGTT-
TCT-3  and 5 -GGTCACAGGCCGCTTTATGTT-3 β-actin,
5 -TGGAATCCTGGTCCATGAAAC-3  and 5 -GTCACA-
GTCAGCTGTATAGGG-3 .
Proinﬂammatory gene expression was analyzed with
SYBR Green PCR Mastermix (ABl) and a ﬁnal concentration
of 200nM primers, using β-actin as the internal standard.
The following PCR proﬁle was used: 2 minutes at 50◦C, 10
minutes at 94◦C, and 40 cycles of 1 minute at 94◦C, and 1
minute at 60◦C. The amount of SYBR Green was measured
at the end of each cycle. The cycle number at which the emis-
sion intensity of the sample rises above the baseline is re-
ferredas to the relative quantitative (RQ)andis proportional
to the target concentration. Real-time PCR was performed
in duplicate and analyzed by applied Biosystems 7500 Fast
Real-Time PCR system manual (threshold: 0.05; baseline: 6–
15 cycles). To generate the standard curves for Proinﬂamma-
tory cytokine and β-actin, serially diluted cDNA (1/1-1/16)
was prepared and real-time PCR was performed as above.
Relative quantitative (RQ) evaluations by RQ-PCR were ex-
pressed at various samples.
H&EandM-TstaininginmurineOVA-induced
asthmalungtissue
Three experimental groups were treated with diﬀerent con-
centrations of RAE ﬁve times a week and CsA three times a
week for the later 8 weeks. At the end of the experiment, the
mice lung sections were stained with H&E and M-T and an-
alyzed histologically by modiﬁed protocol as previously de-
scribed [17, 18].
Statiscalanalysis
For statistical analysis of data, P values were analyzed us-
ing a student’s t-test software program (Startview 5.1; Aba-
cus Concepts, Berkeley, Calif, USA). Results were considered4 Mediators of Inﬂammation
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Figure 1: Eﬀects of RAE and CsA on methacholine-induced AHR
in the sensitization (NM: normal C57BL/6 mice; CT: OVA-induced
asthma mice (control); CsA: OVA-induced asthma mice treated
with cyclosporine A (10mg/kg); RAE 450mg/kg: OVA-induced
asthma mice treated with RAE (450mg/kg); RAE 45mg/kg: OVA-
induced asthma mice treated with RAE (45mg/kg)).
statistically signiﬁcant when P values were ∗P<. 05, ∗∗P<
.01, and ∗∗∗P<. 001.
3. RESULTS AND DISCUSSION
First, we examined how RAE made an eﬀect toward CD4+
T cells in vitro. Splenocytes were isolated from naive
C57bl/6 mice. CD4+ T cells were selected on a CS column,
and the ﬂow-through was collected as CD4+ T cells. Iso-
lated cells were activated by overnight incubation on 24-
well plates coated with 1μg/mL anti-CD3, 1μg/mL anti-
CD28, and with RAE (100, 50, 10μg/mL) and CsA (Cy-
closporine A 10μg/mL) added to RPMI medium supple-
mented with 1 unit/mL penicillin, 1μg/mL streptomycin,
20mM L-glutamine, 50mM-mercaptoethanol, and 5% FBS
for 48 hours after stimulation. After 48-hour culture, sam-
ples were centrifuged at 2000rpm for 10 minutes. Mouse
IL-4, IL-5, IL-13, and IFN-γ. The levels of cytokines were
quantiﬁed using ELISA kits according to the manufacturer’s
protocols. As you see Table 1, RAE decreased IL-4, IL-5, and
IL-13 cytokines, It has been suggested that RAE may be has
suppressing activities of CD4+ T cells, eosinophils inducing
asthmatic inﬂammations.
The results expressed the mean ± S.E (N = 6). Statisti-
cally signiﬁcant value compared with control group data by
t-test (∗∗∗P<. 001, ∗∗P<. 01, ∗P<. 05).
To evaluate the eﬀects of RAE and CsA on airway hy-
perresponsiveness, total pulmonary airﬂow in mice was es-
timated in murine model of asthma. Penh was measured by
Buxco system on day 1 after ﬁnal inhalation and then im-
mediately samples were collected. Exposure of animals to
aerosolized OVA resulted in increased airway hyperrespon-
siveness (AHR) compared with that of animals receiving PBS
only (Figure 1). As shown in Figure 1, relative to animals
sensitized with OVA (control group), RAE-(450mg/kg) and
CsA-(10mg/kg) treated groups showed a signiﬁcant (∗∗p<
.01, ∗∗∗p<. 001) decrease in methacholine-induced AHR.
But RAE (45mg/kg) group did not show signiﬁcant decrease
in Penh value. This was accompanied by changes in the lung
and BAL total cells counts (Figure 4). Therefore, above re-
sults indicate that RAE (450mg/kg) and CsA have inhibitory
eﬀects on AHR.
Statistically signiﬁcant, value compared with control by
t-test (∗P<. 05, ∗∗P<. 01).
To clarify the eﬃcacy of RAE on lung cells of murine
asthma model, the left lungs were histologically examined 24
hours after the ﬁnal antigen challenge. Histological analyses
of lungs from PBS-exposed sensitized mice showed normal
lung histology (Figures 2(a), 3(a)). In contrast, similar to the
BALF study, histological sections of lung tissue from OVA-
exposed mice exhibited airway inﬂammation and inﬁltrat-
ing eosinophils werechieﬂyobserved in theperibronchialre-
gionsofthelung(Figures2(b),2(c),3(b),3(c)).Whileonthe
otherhand,exhibitionofairwayinﬂammationwasdecreased
in histological sections of lung tissue from RAE and CsA
(Figures2(d),3(d)),RAE450mg/kg(Figures2(e),3(e)),and
RAE45mg/kg-treatedmice(Figures2(f),3(f)).Thelungtis-
sue of CsA and RAE treatments on mice group showed much
less eosinophils, leukocytes, and collagenaccumulating com-
pared with that of OVA-induced mice group.
The number of BAL eosinophils was sequentially in-
creased after two or three consecutive days of OVA exposure.
To evaluate the eﬀect of RAE and CsA on the recruitment
of cells to the airway, we investigated the lung weight, to-
tal lung cell, total leukocytes, and eosinophils in BALF. In
RAE and CsA-treated groups, total lung weight was signiﬁ-
cantly reduced compared with OVA-exposed control group,
and the number of total leukocytes in BALF, total lung cells,
and eosinophils were also signiﬁcantly reduced compared to
those in the control group (Figure 4).
C57BL/6 mice were injected, inhaled, and sprayed with
ovalbumin (OVA) for 8 weeks (ﬁve times a week) for asthma
induction. Two experimental groups were treated with dif-
ferent concentrations of Radix Adenophorae extract (RAE)
for the later 8 weeks (ﬁve times a week). At the end of the
experiment, the mice lungs were removed and weighted.
The cell surface expression of CCR3 was analyzed by
ﬂow cytometry. To detect CCR3 expression on lung, lymph
node, BALF, and spleen cells, two-color immune-staining
was performed using FITC-conjugated anti-CCR3 with PE-
conjugated anti-CD3 mAb as described in materials and
methods.
To evaluate the eﬃcacy of RAE and CsA treatments on
granulocytespopulationandCCR3expression,wecompared
the eﬀects of RAE and CsA on intracellular CCR3 expres-
sion in OVA-induced asthma lung cells by using ﬂow cytom-
etry. The percentages of CCR3-positive cells were decreased
when compared with control group (∗∗P<. 01, Figure 5).
ResultsobtainedwithFACSwerealsoconﬁrmedbyreal-time
PCR, as the relative quantitiveness RQ of mRNA expression
in lung cells expressing CCR3 was signiﬁcantly decreased in
cells treated with RAE and CsA when compared with control
group (Table 3). Moreover, RAE and CsA treated group with
OVA resulted in signiﬁcant reductions Gr-1+/CD11b+ cells
in lung (∗∗P<. 01) (Figure 6).Seong-Soo Roh et al. 5
Table 1: Eﬀe c t so fR A Eo nc y t o k i n e si nC D 4 + t cells isolated from Naive C57bl/6 Mice (NM: Normal C57BL/6 mice; CT: a-CD3/CD28+
CD4+ T cells; CsA: a-CD3/CD28+ CD4+ T cells + CsA; RAE 100: a-CD3/CD28+ CD4+ Tc e l l s+R A E( 1 0 0μg/mL); RAE 50 : a-CD3/CD28+
CD4+ T cells + RAE (50μg/mL); RAE 10 : a-CD3/CD28+ CD4+ T cells + RAE (10μg/mL)).
IFN-gamma (pg/mL) IL-4 (pg/mL) IL-5 (pg/mL) IL-13 (pg/mL)
NM 1023.8 ± 39.3 693.8 ± 109.9 1.0 ± 0.2 15.2 ± 1.0
CT 1452.5 ± 62.4 4681 ± 303.5 54.5 ± 5.1 515.5 ± 18.7
CsA 809 ± 32.2∗∗∗ 537 ± 84.3∗∗∗ 3.9 ± 0.4∗∗∗ 15.4 ± 0.7∗∗∗
RAE 100 2028.9 ± 192.9∗ 2859.5 ± 198.7∗∗ 21.7 ± 1.4∗∗∗ 316.2 ± 32.6∗∗∗
RAE 50 1529.1 ± 159.9 3114.1 ± 76.2∗∗ 28.3 ± 2.7∗∗ 394.4 ± 21.7∗∗
RAE 10 1335.4 ± 55.6 3597.2 ± 434.7 56.7 ± 4.6 496.5 ± 7.2
Table 2: Eﬀects of RAE on CD4+/CD8−,G R - 1 +/CD11b+,I g E +/B220+,a n dC D 3 e +/CD69+ cells absolute number in lymph nodes and BAL
ﬂuid of OVA-induced asthma murine.
Cell phenotype Organ Normal C57BL/6 OVA-induced asthma mice (Absolute no.)
Control CsA RAE (450) RAE (45)
CD4+/CD8− (×104 cells) LN
1 221.9 ± 34.9 232.7 ± 12.8 150.3 ± 41.1∗∗ 193.95 ± 10.1∗ 244.7 ± 32.2
BA
2 3.9 ± 0.6 33.6 ± 0.8 13.2 ± 3.1∗∗ 11.3 ± 0.1∗∗ 27.7 ± 1.5∗
Gr-1+/CD11b
+ (×104 cells) LN
1 25.6 ± 0.5 73.6 ± 13.8 45.0 ± 11.9∗∗ 33.7 ± 1.0∗∗ 45.6 ± 8.6∗
IgE
+/B220+ (×104 cells) LN
1 3.6 ± 0.1 6.6 ± 1.2 3.6 ± 1.1 2.1 ± 0.3∗ 3.0 ± 0.9
BA
2 0.3 ± 0.01 2.6 ± 0.07 0.5 ± 0.03∗∗ 0.5 ± 0.02∗∗ 1.1 ± 0.05∗
CD3+/CD69+ (×104 cells) LN
1 32.5 ± 3.0 54.2 ± 1.4 35.6 ± 8.1 36.6 ± 1.9 47.6 ± 7.1
Table 3: Eﬀect of RAE on Eotaxin2, CCR3, IL-13, IL-10, TNF-α, and TARC mRNA expression in lung tissue of OVA-induced murine model
of asthma (NM: normal C57BL/6 mice; CT: OVA-induced asthma mice (control); CsA: OVA-induced asthma mice treated with cyclosporine
A (10mg/kg); RAE 45mg/kg: OVA-induced asthma mice treated with RAE (450mg/kg); RAE 450mg/kg: OVA-induced asthma mice treated
with RAE (450mg/kg)).
OVA/alum Group Exotaxin2 CCR3 IL-10 IL-13 TARC TNF-α
− NM 0.02 0.03 0.05 0.016 0.656 0.152
+C T 1 1 1 1 1 1
+ CsA 0.202 0.404 0.621 0.386 0.12 0.255
+ RAE (450mg/kg) 0.462 0.499 0.577 0.284 0.487 0.401
+ RAE (45mg/kg) 0.62 0.725 0.504 0.763 0.944 0.625
(a) (b) (c) (d) (e) (f)
H&E
M-T
Figure 2: Eﬀect of RAE on histology of lung tissue (H&E and Masson trichrome staining) in lung tissues of OVA-induced asthma murine
((a): normal C57BL/6 mice; (b): OVA-induced asthma mice (Control 1); (c): OVA-induced asthma mice (Control 2); (d): OVA-induced
asthma mice treated with cyclosporine A (10mg/kg); (e): OVA-induced asthma mice treated with RAE (450mg/kg); (f): OVA-induced
asthma mice treated with RAE (45mg/kg)).6 Mediators of Inﬂammation
(a) (b) (c)
(d) (e) (f)
Figure 3:EﬀectofRAEonimmunohistochemistryoflungtissue(Congoredstain)inlungtissuesofOVA-inducedasthmamurine((a):nor-
mal C57bl/6 mice; (b) and (c): OVA-induced asthma mice (control); (d): OVA-induced asthma mice treated with cyclosporine A (10mg/kg);
(e): OVA-induced asthma mice treated with RAE (450mg/kg); (f): OVA-induced asthma mice treated with RAE (45mg/kg)).
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Figure 5: Eﬀect of RAE on CD3e−/CCR3+ population in lung
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C57BL/6 mice were injected, inhaled, and sprayed with
OVA for 8 weeks (ﬁve times a week) for asthma induction.
Twoexperimentalgroupsweretreatedwithdiﬀerentconcen-
trations of RAE for the later 8 weeks (ﬁve times a week). At
the end of the experiment, the mice lungs were removed and
analyzed by ﬂow cytometer.
Eﬀects of RAE on leukocyte subsets in lungs and BALF
were marked with change in numbers of CD4+/CD8− T
cells (Th2 cells). CD3 +/CD69+ (early activated T cells)
IgE+/B220+ B cells in a murine model of asthma compared
to control group, and the deﬁcits in CD4+/CD8− Tc e l l s
were accompanied by concurrent decreases in absolute num-
ber of CD3+/CD69+,I g E +/B220+ B cells (Table 2, Figure 6).
RAE and CsA groups treated with OVA resulted in further
signiﬁcant reductions in CD4+/CD8− T cells (∗∗P<. 01)
and IgE+/B220+ B cells (∗∗P<. 01) in BALF and lung tis-
suessigniﬁcantlyweredecreasedandCD4+/CD8− Tcellsand
CD3+/CD69+ cells (∗∗P<. 01) in lung tissues signiﬁcantly
were also decreased (Table 2, Figure 6).
Each point represents the mean ± S.E of 6 mice. Sta-
tistically signiﬁcant, value compared with control by t-test
(∗P<. 05, ∗∗P<. 01) (LN1: Lymph node; BA2:B r o n -
choalveolar Lavage).
To study whether RAE was related to inﬂammatory cy-
tokine production, BALF supernatants were collected, and
the productions of IL-4, IL-5, IL-10, IL-13, IgE, histamine
were analyzed by ELISA. Asshown in Figure 7, IL-4, IL-5, IL-
13, IgE productions in BALF and histamine production in
serum were suppressed by RAE and CsA. Both IL-4 and IL-
13 levels were signiﬁcantly reduced in RAE- and CsA-treated
groups of mice.
Because IgE levels in BALF are dependent upon IL-4, IL-
5, IL-13 and may be considered an additional index of Th2
cytokinesecretion,wemeasuredIgEinBALFfrommiceinall
groups. We foundthatIgElevelsin BALFfromOVA-induced
murine model of asthma were signiﬁcantly increased com-
pared with normal groups. RAE and CsA treatments of these
mice signiﬁcantly inhibited the production of IgE. These re-
sults support the conclusion that RAE and CsA suppressed
the generation of a Th2-type immune response and activity
of mast cells in this animal model of asthma.
To investigate the eﬀect of RAE on mRNA expression in
lung tissue, total cellular RNA was extracted from lung cells
treated with or without RAE in the presence or absence of
OVA sensitization and inhalation. As shown in Table 3, the
mRNA for eotaxin2, CCR3, IL-13, IL-10, TARC, and TNF-α
was detectable in the lung cells treated with PBS only (NM),
OVA (CT), CsA (10mg/kg), and RAE (450, 45mg/kg), re-
spectively (Table 3).
C57BL/6 mice were injected, inhaled and, sprayed with
OVA for 8 weeks (ﬁve times a week) for asthma induction.
Twoexperimentalgroupsweretreatedwithdiﬀerentconcen-
trations of Radix Adenophorae extract (RAE) for the later 8
weeks (ﬁve times a week). At the end of the experiment, the
mice lungs were removed and analyzed by real-time PCR.
PCR products for eotaxin2, CCR3, IL-13, TARC, and
TNF-α ampliﬁed from lung cell RNA preparations were de-
creased in the RAE-treated groups compared with control
groups. Furthermore, the RAE had little eﬀects on IL-10
mRNA expression in lung cells (Table 3). The results demon-
strated that RAE and CsA signiﬁcantly aﬀected eotaxin2,
CCR3, IL-13, TARC, and TNF-α mRNAs expression but
not other cytokines in lung cells. This was accompanied by
changes in the eosinophil inﬂux (Figure 5), BAL cytokines
(IL-13) production (Figure 7)i ns o m ed e g r e e .
C57BL/6 mice were injected, inhaled, and sprayed with
OVA for 8 weeks (ﬁve times a week) for asthma induction.
Twoexperimentalgroupsweretreatedwithdiﬀerentconcen-
trations of Radix Adenophorae extract (RAE) for the later 8
weeks (ﬁve times a week). At the end of the experiment, the
BALFwerecollectedandcytokineproductionswereanalyzed
by ELISA.
Bronchial asthma is a chronic inﬂammatory disorder of
the airways characterized by variable airway obstruction, air-
way eosinophilic inﬂammation, and AHR [19]. Persistent in-
ﬂammation of bronchial mucosa, mainly characterized by
eosinophilic inﬁltration, is considered as an essential process
in the pathogenesis of asthma [20, 21].
Asthma is a chronic lung disease characterized by
allergen-induced airway inﬂammation and orchestrated by
Th2 cells [22]. RAE is one of the well known herbs used in
oriental medicine for treatment of anti-inﬂammatory and
many allergic diseases.
Anti-inﬂammatory eﬀects of RAE on the development
of OVA-induced eosinophilia and hyperresponsiveness in
murine model of asthma have not been fully investigated in
vivo.
Immunomodulators such as cyclosporine A (CsA) in-
hibit single allergen-induced allergic inﬂammation such as
eosinophilic, lymphocytic inﬁltration,and mRNA expression8 Mediators of Inﬂammation
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induced asthma mice treated with RAE (45mg/kg)).
for IL-4 and IL-5 [23]. In this study, the RAE could modulate
the immune responses of BALF cells and lung cells in OVA-
induced murine model of asthma. Hence, the suppressive ac-
tivity of RAE and CsA on inﬂammatory cytokine produc-
tions might have important implications with regard to RAE
therapeuticactivityinasthmaandpulmonaryinﬂammation.
The main question to be addressed is whether RAE is in-
volved in the pathology of airway inﬂammation and asthma.
In the present study, we examined lung cells inﬂammation
and BALF analyses.
Airwayallergenchallengecausescellularinﬂammationin
the airways, which is dominated by eosinophils in both hu-
mans and mice [24]. It has been suggested that eosinophils
contribute to several of the clinical features of allergic
asthma, including tissue damage and AHR [25].
We measured the eﬀects of RAE on methacholine-
induced AHR in the sensitization. As shown in Figure 1,r e l -
ative to animals sensitized with OVA (control group), RAE-
(450mg/kg) and CsA-(10mg/kg) treated groups showed a
signiﬁcant decrease in methacholine-induced AHR. This was
accompanied by changes in the lung and BAL total cells
counts (Figure 4). Therefore, above results indicate that RAE
(450mg/kg) and CsA have inhibitory eﬀects on airway hy-
perresponsiveness.
In aspect of histological analyses of sections from OVA-
induced asthma model mice, the lung tissue of CsA and RAE
treatments of mice group showed much less eosinophils,
leukocytes, and collagen accumulating compared with that
of OVA-induced mice group (Figures 2, 3).
To evaluate the eﬀect of RAE and CsA on the recruitment
of cells to the airway, we investigated the lung weight, total
lungcell,totalleukocytes,andeosinophilsinBALF.Ingroups
treated with RAE and CsA, total lung weight was signiﬁ-
cantly reduced compared with OVA-exposed control group,Seong-Soo Roh et al. 9
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Figure 7: Eﬀect of RAE on cytokines, immunoglobulin E levels in BALF and histamine release in serum (NM: normal C57BL/6 mice;
CT: OVA-induced asthma mice (control); CsA: OVA-induced asthma mice treated with cyclosporine A (10mg/kg); RAE 450mg/kg: OVA-
induced asthma mice treated with RAE (450mg/kg); RAE 450mg/kg: OVA-induced asthma mice treated with RAE (450mg/kg)).
and the number of total leukocytes in BALF, total lung cells,
and eosinophils was also signiﬁcantly reduced compared to
those in the control group (Figure 4). These results indicate
that RAE (450mg/kg) and CsA have inhibitory eﬀects on
eosinophils and leukocytes inﬁltration into the lungs.
Antigen-activated CD4+ T cells have been shown to in-
duce many of the characteristic features of asthma, includ-
ing the secretion of cytokines such as IL-4, IL-5, and IL-13,
which regulate mucus production, inﬂammation, and adhe-
sion molecules [26–28].
High levels of interleukin-4 and interleukin-5 are related
to clinical measures of disease severity [29, 30]; IL-5 has been
shown to mediate the recruitment of eosinophils [31]. The
reductioninBALIL-13levelswouldsuggestabeneﬁcialther-
apeutic eﬀect via decreased mucus production [32].
To evaluate the eﬃcacy of RAE and CsA treatments on
granulocytespopulationandCCR3expression,wecompared
the eﬀects of RAE and CsA on intracellular CCR3 expres-
sion in OVA-induced asthma lung cells by using ﬂow cytom-
etry. The percentages of CCR3-positive cells were decreased
when compared with control group (Figure 5). Results ob-
tained with FACS were also conﬁrmed by real-time PCR,
as the relative quantitiveness RQ of mRNA gene expression
in lung cells expressing CCR3 was signiﬁcantly decreased in
cells treated with RAE and CsA when compared with control
group(Table 3).OurresultsindicatethatRAEcoulddecrease
CCR3 expression of BALF cells (especially eosinophils), data
of which are compatible with airway eosinophil inﬂux and
hyperresponsiveness.
CD11b expression on the surface of circulating eosino-
phils is signiﬁcantly elevated in various allergic disorders, in-
cluding atopic dermatitis and bronchial asthma [33]. We ob-
served that inhalation challenge with RAE and CsA adminis-
tration resulted in a decrease in airway CD11b+ macrophage,
Gr-1 granulocytes when compared with that observed af-
ter OVA challenge only. RAE and CsA groups treated with
OVA resulted in signiﬁcant reductions Gr-1+/CD11b cells
in lung and lymph nodes (Table 2, Figure 6). Our results
show that RAE and CsA downregulate CCR3 expression and
CD4+CD8− T cells, CD3+ CD69+,I g E + B220+ Bc e l l si n
BALF and lung cells (Table 2, Figure 6).
In study, various cytokines production of BALF cells
from OVA-induced control subjects have been enhanced,
but RAE- and CsA-treated subjects signiﬁcantly reduced. We
suggest that the inhibitory mechanism of RAE and CsA on
IL-4, IL-5, IL-10, and IL-13 production may have involved
reduced production of IL-4, IL-5, IL-13, IgE and this would
suppress the eosinophils inﬂux in airway and then more fac-
tors synthesized by RAE and CsA treated in BALF such as IgE
were decreased (Figure 7). This was accompanied by changes
in the BAL eosinophils counts (Figure 4)a n dm R N Ae x p r e s -
sion in lung tissue (Table 3).
RAE decreased IL-4, IL-5, and IL-13 levels in BALF
and histamine release in serum signiﬁcantly (Figure 7), and
mRNA expression of IL-13 in the lung as well (Table 3). The
lung histology in our study (Figures 2, 3) showed that RAE
reduced the eosinophils in lung tissue, and this result may
be due to the decreased IL-4 level which caused reduction in
rolling and adhesion of eosinophils. Based on these results, it
isinferredthatRAEmayhaveanantiallergiceﬀectonallergic
bronchial asthma via suppressing IL-4 secretion, and in con-
sequence, inhibiting IgE secretion from B cells, and reduced
IL-4mayreduceeosinophilsinﬁltrationintothelungsviare-
ducing the rolling on and adhesion of circulating eosinophils
to the endothelial cells.
IL-5 is a Th2-type cytokine that promotes the recruit-
ment and activation of eosinophils. IL-5 stimulates the re-
leaseofchemicalmediatorsfromtheeosinophils[34].There-
fore, IL-5 has been implicated in the pathogenesis of aller-
gic diseases [35], and many studies have focused IL-5 to be a10 Mediators of Inﬂammation
viable target for the treatment of asthma and allergic diseases
[36].
In our study, RAE signiﬁcantly reduced IL-5 levels in
BALF (Figure 7)a sw e lla sm R N Ae x p r e s s i o no fI L - 1 3i nl u n g
(Table 3). Like this, RAE reduced eosinophils inﬁltration and
activation in OVA-induced asthmatic mice. We considered
that this action may be due to inhibiting IL-13, IL-5 secre-
tion from Th2 cells.
These results indicate that RAE may suppress the excess
activity of T cells and Th2 cytokines, which are implicated in
the pathogenesis of allergic asthma, and consequently regu-
late the Th1/Th2 imbalance of the immune system in allergic
asthma. From these results, we hypothesize that RAE has an
immunoregulatory function between Th1 and Th2, and sup-
pressive eﬀect on excessive Th2 cytokines.
Th2 cytokines as well as elevated IgE levels are associated
with the development of airway hyperreactivity. Especially,
IL-13 has been shown to mediate the airway hyperrespon-
siveness in an allergic lung in several studies [37].
Furthermore, mRNA expressions of these cytokines in
lung were reduced remarkably by RAE (Table 2). From these
results,wepresumethatRAEmaysuppresstheairwayhyper-
responsiveness by way of reducing these cytokines.
Cytokines and chemokines produced by Bronchial ep-
ithelial cells include IL-6, IL-8, G-CSF, GM-CSF, RANTES,
eotaxin, and TARC. Proinﬂammatory cytokines IL-1 and
TNF-alphagenerallyup-regulateexpressionandreleasethese
cytokines/chemokines [38].
The bronchial epithelium of asthmatics and normal sub-
jects expressed TARC protein, and the asthmatics showed
more intense expression than the normal subjects. And com-
bination of TNF-alpha and IL-4 induced expression of TARC
protein. Furthermore, expressions of TARC protein and
mRNA were almost completely inhibited by glucocorticoids.
The airway epithelium represents an important source of
TARC, which potentially plays a role via a paracrine mecha-
nism in the development of allergic respiratory diseases [39].
Our study shows that eotaxin2, TNF-α,a n dT A R C
mDNA gene expression in lung cells were signiﬁcantly de-
creased in cells treated with RAE and CsA when compared
with control group (Table 3). Our results indicate that RAE
may have eﬀects of antibronchial injury, data of which are
compatible with airway eosinophils inﬂux and hyperrespon-
siveness. So histological analyses of sections from OVA-
induced asthma model mice, the lung tissue of CsA and RAE
treatments of mice group showed much less eosinophils,
leukocytes, and collagen accumulating compared with that
of OVA-induced mice group (Figures 2, 3).
In summary, RAE and CsA have profound eﬀects on air-
way inﬂammation and AHR in a murine model of asthma
through suppression of IL-13, IL-5, IgE, eosinophils CCR3
expression, and CD11b cells expression. The therapeutic ac-
tivity of RAE on asthma in oriental medicine may be partly
related tothe following. (a) Immunomodulatory agents con-
tained in RAE reduce Th2 cells immune responses. (b) Re-
duced production of IgE will make a marked decrease for
asthma attack occurring in individuals. (c) RAE may have an
eﬀect of suppressing eosinophils activity and decrease airway
damage.
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